Pharmacogenomic Evaluation of Antihypertensive Responses 2
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 839 participants.
Also called NCT01203852
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 839 participants
- Sponsor
- Registry
-
NCT01203852
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01203852. Allocation not applicable; no masking; primary purpose treatment. Start 2010-08 (registry gives no type); primary completion 2014-04 (actual). Results posted on 2015-05-19.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Pharmacogenomic Evaluation of Antihypertensive Responses 2
- Acronym
- PEAR2
- Condition
- Hypertension
- Intervention (Drug)
- Metoprolol
- Intervention (Drug)
- Chlorthalidone
- Lead sponsor
- University of Florida
- Collaborator
- National Institute of General Medical Sciences (NIGMS)
Record details
- Record id
cardio:ct-nct01203852- Content hash
6f7f9c8bef9e7c30c139d7888577bee26eff69add667986de7011103a722fb7a